Ed Arce
Stock Analyst at WestPark Capital
(4.15)
# 505
Out of 5,046 analysts
449
Total ratings
46.01%
Success rate
16.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $10.93 | +156.18% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $35.16 | -14.68% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.99 | +1,109.07% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.75 | +1,478.95% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $9.97 | +501.81% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.21 | +239.37% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.30 | +202.33% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $5.81 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.34 | +347.76% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $8.25 | +748.48% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $31.05 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $5.02 | +4,680.88% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.68 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.52 | +275.59% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $109.24 | -67.96% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $54.20 | +38.38% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $72.65 | -0.89% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $418.90 | -3.32% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.06 | -9.24% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $34.60 | +174.57% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.86 | +236.79% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.73 | +5.71% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $37.94 | +26.52% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $8.26 | -9.20% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.67 | +646.27% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $13.17 | -1.29% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.69 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $28.46 | -12.16% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.37 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.91 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $38.08 | -81.62% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $36.00 | -41.67% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.24 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $10.93
Upside: +156.18%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $35.16
Upside: -14.68%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.99
Upside: +1,109.07%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.75
Upside: +1,478.95%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $9.97
Upside: +501.81%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.21
Upside: +239.37%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.30
Upside: +202.33%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.81
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.34
Upside: +347.76%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $8.25
Upside: +748.48%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $31.05
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $5.02
Upside: +4,680.88%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $8.52
Upside: +275.59%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $109.24
Upside: -67.96%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $54.20
Upside: +38.38%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $72.65
Upside: -0.89%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $418.90
Upside: -3.32%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.06
Upside: -9.24%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $34.60
Upside: +174.57%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.86
Upside: +236.79%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.73
Upside: +5.71%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $37.94
Upside: +26.52%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $8.26
Upside: -9.20%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.67
Upside: +646.27%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $13.17
Upside: -1.29%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $28.46
Upside: -12.16%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.91
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $38.08
Upside: -81.62%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $36.00
Upside: -41.67%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.24
Upside: -